The researchers characterized how gene therapy affects the immune cell repertoires and microbiomes of X-linked severe combined immunodeficiency patients.
The company shared early evidence of the potential of its approach to improve newborn screening for immune disorders, and to offer new tools for other areas like HIV monitoring.
Using the method, the researchers predicted the effects of over 140 million mutations in different tissues and identified mutations possibly associated with increased risk of several immune diseases.
Researchers provided genetic diagnoses for about 68 percent of their primary antibody deficiency cohort, which altered clinical management in about half of them.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
NanoString Technologies this week provided investors with a mixed bag of news as it released its second quarter earnings and financial outlook for the rest of the year.
A curation working group established a framework that considers the nature and strength of the available evidence when evaluating gene-disease associations.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
